Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • May 2024
  • Article
  • Journal of the American College of Radiology

True Costs of Uterine Artery Embolization: Time-Driven Activity-Based Costing in Interventional Radiology Over a 3-Year Period

By: Julia C. Bulman, Nicole H. Kim, Robert S. Kaplan, Sarah Schroeppel DeBacker, Olga R. Brook and Ammar Sarwar
  • Format:Electronic
  • | Pages:8
ShareBar

Abstract

The study used time-driven activity-based costing (TDABC) to estimate the costs to perform uterine artery embolization (UAE). Utilization times for patients undergoing outpatient UAE for fibroids or adenomyosis were captured from electronic health record timestamps and staff interviews. Capacity cost rates were estimated using institutional data and manufacturer proxy prices. Costs were calculated using TDABC for personnel, equipment, and consumables. The mean total cost of UAE was $4,267, with the greatest contributor being consumables (51%), followed by personnel (33%), and equipment (7%). Embolic agents accounted for 51% of consumable costs, followed by vascular devices (15%). The cost of embolic agents was driven mainly by the number of vials used.

Keywords

Cost Accounting; Health Care and Treatment; Health Industry

Citation

Bulman, Julia C., Nicole H. Kim, Robert S. Kaplan, Sarah Schroeppel DeBacker, Olga R. Brook, and Ammar Sarwar. "True Costs of Uterine Artery Embolization: Time-Driven Activity-Based Costing in Interventional Radiology Over a 3-Year Period." Journal of the American College of Radiology 21, no. 5 (May 2024): 721–728.
  • Read Now

About The Author

Robert S. Kaplan

Accounting and Management
→More Publications

More from the Authors

    • February 2025
    • NEJM Catalyst Innovations in Care Delivery

    Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States

    By: Emma Brady, Ryan C. Perkins, Kate Cullen, Gregory S. Sawicki, Robert S. Kaplan and Gerardine Doyle
    • September 26, 2024
    • Harvard Business Review Digital Articles

    A Better Way to Measure Social Impact

    By: Robert S. Kaplan and Constance Spitzer
    • July–August 2024
    • Harvard Business Review

    Disclosing Downstream Emissions

    By: Robert S. Kaplan and Karthik Ramanna
More from the Authors
  • Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States By: Emma Brady, Ryan C. Perkins, Kate Cullen, Gregory S. Sawicki, Robert S. Kaplan and Gerardine Doyle
  • A Better Way to Measure Social Impact By: Robert S. Kaplan and Constance Spitzer
  • Disclosing Downstream Emissions By: Robert S. Kaplan and Karthik Ramanna
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.